Starboard has approached two former Pfizer executives, Ian Read and Frank D’Amelio, to assist in its efforts, and they have ...

The Federal Trade Commission staff is criticizing pharmaceutical benefit managers, which negotiate drug discounts. But ...

On Thursday, H.C. Wainwright maintained its Buy rating and $10.00 stock price target for Lexicon Pharmaceuticals (NASDAQ ... primarily from INPEFA sales. H.C. Wainwright maintained its Buy rating ...

Lexicon Pharmaceuticals Inc (LXRX) stock saw a modest uptick, ending the day at $1.69 which represents a slight increase of $0.08 or 4.97% from the prior close of $1.61. The stock opened at $1.63 and ...

Following approval, Verona Pharma launched the drug in late July. The company is expected to report its first-quarter sales in early ... with a steady price target of $36.00.

Following approval, Verona Pharma launched the drug in late July. The company is expected to report its first-quarter sales in early November ... with a steady price target of $36.00. This follows ...

Biomarin Pharmaceutical Inc (BMRN) stock saw a decline, ending the day at $68.16 which represents a decrease of $-1.50 or -2.15% from the prior close of $69.66. The stock opened at $69.58 and touched ...

Arrowhead's plozasiran shows promising Phase 3 data for FCS, with potential blockbuster status, but faces competition. Learn ...

The pharmaceutical industry plays a crucial role in most of our everyday lives. From life-saving medication we need when we ...

Johnson & Johnson is making the investment to help meet its 2030 target of launching 20 new medicines and expanding filings ...

The path to discovering a blockbuster drug is often unpredictable. A promising molecule might be overlooked for decades, only ...

Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast Truist Securities raises the price target for Corcept Therapeutics to $76 ...